Cas:195136-62-0 1-fluoro-2,4-dimethoxy-5-nitrobenzene manufacturer & supplier

We serve Chemical Name:1-fluoro-2,4-dimethoxy-5-nitrobenzene CAS:195136-62-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

1-fluoro-2,4-dimethoxy-5-nitrobenzene

Chemical Name:1-fluoro-2,4-dimethoxy-5-nitrobenzene
CAS.NO:195136-62-0
Synonyms:PC7348;2,4-Dimethoxy-5-fluoronitrobenzene;1-Fluoro-2,4dimethoxy-5-nitro-benzene
Molecular Formula:C8H8FNO4
Molecular Weight:201.15200
HS Code:2909309090

Physical and Chemical Properties:
Melting point:151-153ºC
Boiling point:321.6ºC at 760 mmHg
Density:1.31 g/cm3
Index of Refraction:
PSA:64.28000
Exact Mass:201.04400
LogP:2.27430

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like PC7348 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-Fluoro-2,4dimethoxy-5-nitro-benzene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-Fluoro-2,4dimethoxy-5-nitro-benzene Use and application,1-Fluoro-2,4dimethoxy-5-nitro-benzene technical grade,usp/ep/jp grade.


Related News: In these situations, the API is not a single substance but the culmination of various ingredients. 1-fluoro-2,4-dimethoxy-5-nitrobenzene manufacturer ��We believe the iLet Bionics Pancreas System represents a true breakthrough therapy for the management of glycemia, particularly in type 1 diabetes,�� said Ed Damiano, President and CEO of Beta Bionics. ��We are partuclarly excited by the possibility that the iLet may be able to provide safer and more effective therapy in far more people than current therapies due to its simplicity of use.�� 1-fluoro-2,4-dimethoxy-5-nitrobenzene supplier But even though weight-loss success depends on adopting a challenging” change in post-operation diet and lifestyle, the process can certainly “help people to lose weight and get comorbid [other negative health] conditions under better control,” Sandon said.
So it’s important, she said, to help eligible patients better “understand the treatment options and potential for success,” by sharing surgery success stories and highlighting the benefits of reducing high-risk health issues such as blood pressure and diabetes.
An experimental Alzheimer’s vaccine appears to safely clear abnormal tau protein from the brain, but it’s not yet clear whether the shot will be able to save brain function.
In a Phase 2 clinical trial, the vaccine produced high levels of antibodies to target and attack free-floating tau proteins before they can form “tau tangles” that clog neurons and damage brain function. Tau tangles, along with plaques formed by the protein amyloid-beta, serve as one of the main hallmarks of Alzheimer’s.
“While amyloid influences speed of Alzheimer’s progression, there is strong evidence that tau pathology relates to the underlying cause of the disease,” said lead researcher Dr. Petr Novak, a senior clinical research scientist at AXON Neuroscience, the Slovakian pharmaceutical company developing the vaccine. “Brain atrophy and cognitive loss closely echo the deposition of pathological tau protein, as evidenced by recent tau PET studies. 1-fluoro-2,4-dimethoxy-5-nitrobenzene vendor But even though weight-loss success depends on adopting a challenging” change in post-operation diet and lifestyle, the process can certainly “help people to lose weight and get comorbid [other negative health] conditions under better control,” Sandon said.
So it’s important, she said, to help eligible patients better “understand the treatment options and potential for success,” by sharing surgery success stories and highlighting the benefits of reducing high-risk health issues such as blood pressure and diabetes.
An experimental Alzheimer’s vaccine appears to safely clear abnormal tau protein from the brain, but it’s not yet clear whether the shot will be able to save brain function.
In a Phase 2 clinical trial, the vaccine produced high levels of antibodies to target and attack free-floating tau proteins before they can form “tau tangles” that clog neurons and damage brain function. Tau tangles, along with plaques formed by the protein amyloid-beta, serve as one of the main hallmarks of Alzheimer’s.
“While amyloid influences speed of Alzheimer’s progression, there is strong evidence that tau pathology relates to the underlying cause of the disease,” said lead researcher Dr. Petr Novak, a senior clinical research scientist at AXON Neuroscience, the Slovakian pharmaceutical company developing the vaccine. “Brain atrophy and cognitive loss closely echo the deposition of pathological tau protein, as evidenced by recent tau PET studies. 1-fluoro-2,4-dimethoxy-5-nitrobenzene factory ��We believe the iLet Bionics Pancreas System represents a true breakthrough therapy for the management of glycemia, particularly in type 1 diabetes,�� said Ed Damiano, President and CEO of Beta Bionics. ��We are partuclarly excited by the possibility that the iLet may be able to provide safer and more effective therapy in far more people than current therapies due to its simplicity of use.��